High DSS1 expression, which potentially stabilizes BRCA2 and maintains cancer cell proliferation, could increase drug resistance under the standard clinical regimens of breast cancer treatment, presumably resulting in decreased disease-free survival. This evidence concerns the gene BRCA2 and breast carcinoma.